BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
07 oct. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
06 oct. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular...
CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
10 sept. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
09 sept. 2021 16h32 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright...
BioCardia to Participate in Upcoming Investor Conferences
13 août 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
12 août 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021
04 août 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies,...
BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
15 juil. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed
23 juin 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...
BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021
22 juin 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...